Regulatory T cells ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
95	自己免疫性肝炎	3
97	潰瘍性大腸炎	2

95. 自己免疫性肝炎

---

臨床試験数 : 52 /  薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03842254 (ClinicalTrials.gov)	January 25, 2019	12/2/2019	Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease	Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease	Autoimmune Hepatitis	Drug: Erythropoietin	Northwestern University	Mount Sinai Hospital, New York;Icahn School of Medicine at Mount Sinai	Completed	18 Years	74 Years	All	6	Early Phase 1	United States
2	NCT02704338 (ClinicalTrials.gov)	April 2016	28/2/2016	Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis	Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in Autoimmune Hepatitis	Autoimmune Diseases	Biological: Regulatory T cells	Nanjing Medical University	NULL	Not yet recruiting	10 Years	70 Years	Both	30	Phase 1/Phase 2	NULL
3	NCT01988506 (ClinicalTrials.gov)	January 6, 2014	7/11/2013	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis	Drug: Interleukin 2	Assistance Publique - Hôpitaux de Paris	Iltoo Pharma	Completed	18 Years	N/A	All	81	Phase 2	France

97. 潰瘍性大腸炎

---

臨床試験数 : 2,630 /  薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04691232 (ClinicalTrials.gov)	February 22, 2021	7/12/2020	Autologous Ex Vivo Expanded Regulatory T Cells in Ulcerative Colitis	Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative Colitis	Ulcerative Colitis;Autoimmune Diseases	Biological: Regulatory T cells	University of Erlangen-Nürnberg Medical School	NULL	Recruiting	18 Years	18 Years	All	10	Phase 1	Germany
2	NCT01988506 (ClinicalTrials.gov)	January 6, 2014	7/11/2013	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis	Drug: Interleukin 2	Assistance Publique - Hôpitaux de Paris	Iltoo Pharma	Completed	18 Years	N/A	All	81	Phase 2	France

先頭へ